Filing Details

Accession Number:
0000950170-24-111737
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-10-02 17:51:30
Reporting Period:
2024-09-30
Accepted Time:
2024-10-02 17:51:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1745999 Beam Therapeutics Inc. BEAM Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
2033155 J Bethany Cavanagh C/O Beam Therapeutics Inc.,
238 Main Street
Cambridge MA 02142
Svp, Finance And Treasurer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-09-30 2,500 $0.00 45,220 No 4 A Direct
Common Stock Disposition 2024-10-01 289 $23.48 44,931 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.
  2. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain RSUs granted to the Reporting Person under the Plan on September 30, 2021. These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.45 to $23.48, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.